Patents by Inventor Li-Long PAN

Li-Long PAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11479588
    Abstract: The disclosure discloses cathelicidin-expressing lactic acid bacteria, and belongs to the technical field of genetic engineering. The disclosure constructs Lactococcus. lactis and Lactobacillus. plantarum expressing a CRAMP protein by optimizing the nucleotide sequence of the CRAMP protein. The Lactobacillus constructed in the disclosure can be used to prepare a vaccine for regulation of intestinal flora disorder, and has advantages in regulation of intestinal flora and intestinal immune response and maintenance. An anaculture can be directly taken as an oral vaccine to stimulate mice and cause a strong cellular immune response. The recombinant L. lactis can be used as a new oral vaccine product with good industrial prospects, plays a positive role in reducing intestinal inflammation, and has important practical significance for promoting health development of the intestinal tract.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: October 25, 2022
    Assignee: Jiangnan University
    Inventors: Jia Sun, Li-Long Pan, Diana Julien, Ming Zhang, Wei Chen, Hao Zhang
  • Publication number: 20220064239
    Abstract: The disclosure discloses cathelicidin-expressing lactic acid bacteria, and belongs to the technical field of genetic engineering. The disclosure constructs Lactococcus. lactis and Lactobacillus. plantarum expressing a CRAMP protein by optimizing the nucleotide sequence of the CRAMP protein. The Lactobacillus constructed in the disclosure can be used to prepare a vaccine for regulation of intestinal flora disorder, and has advantages in regulation of intestinal flora and intestinal immune response and maintenance. An anaculture can be directly taken as an oral vaccine to stimulate mice and cause a strong cellular immune response. The recombinant L. lactis can be used as a new oral vaccine product with good industrial prospects, plays a positive role in reducing intestinal inflammation, and has important practical significance for promoting health development of the intestinal tract.
    Type: Application
    Filed: November 18, 2021
    Publication date: March 3, 2022
    Inventors: Jia SUN, Li-Long PAN, DIANA Julien, Ming ZHANG, Wei CHEN, Hao ZHANG